##common.pageHeaderLogo.altText##

Original article

Vol. 156 No. 2 (2026)

Trends over time and risk factors in inappropriate prescribing in older adults with multimorbidity and polypharmacy: a longitudinal secondary analysis of the OPERAM trial

Cite this as:
Swiss Med Wkly. 2026;156:4892
Published
12.02.2026

Summary

 

BACKGROUND AND AIM OF THE STUDY: Polypharmacy is common among older adults and associated with potentially inappropriate medications and potential prescribing omissions, which together constitute potentially inappropriate prescriptions, contributing to adverse outcomes and increased healthcare costs. Longitudinal data on potentially inappropriate prescriptions and differences across living environments are limited. Our aim was to analyse patterns and determinants of potentially inappropriate prescriptions in multimorbid, older adults across different living environments and their trends over 12 months.

METHODS: We used data from the control group (n = 1045) of the multi-country OPERAM trial (December 2015 – October 2018), a cluster-randomised controlled trial including older adults aged ≥70 years with ≥3 chronic conditions and ≥5 medications, which tested a software intervention to improve prescribing in these patients. The control group received pharmaceutical care in accordance with usual care. STOPP/START criteria were applied to detect potentially inappropriate prescriptions at hospital admission, discharge, and at 2-, 6- and 12-month follow-up. The outcomes were a priori defined as the prevalence of potentially inappropriate prescriptions at hospital admission, differences in potentially inappropriate prescriptions between living settings (nursing home versus community-dwelling) and number of medications (polypharmacy [5–9 medications] versus hyperpolypharmacy [≥10 medications]), changes in potentially inappropriate prescriptions over the 12-month follow-up and factors associated with potentially inappropriate prescriptions. Analyses included descriptive statistics and multivariable regression.

RESULTS: At admission, 664 (63.5%) patients had ≥1 potentially inappropriate medication and 754 (72.1%) had ≥1 potential prescribing omission. Potentially inappropriate prescriptions at admission were most strongly associated with hyperpolypharmacy (potentially inappropriate medication: incidence rate ratio [IRR] 1.54, 95% CI 1.35–1.76) and cognitive impairment (potentially inappropriate medication: IRR 1.44, 95% CI 1.16–1.79), and were also significantly associated with female sex, number of comorbidities, fall history, nursing home residency and older age. Although overall prevalence remained stable over 12 months, substantial individual-level changes occurred, with many patients experiencing increases or decreases in the number of potentially inappropriate medications or potential prescribing omissions, alongside notable shifts in specific potentially inappropriate medications/potential prescribing omissions. An increasing number of potentially inappropriate prescriptions over time was mostly associated with hyperpolypharmacy (potential prescribing omission: OR 1.71, 95% CI 1.20–2.42 at 12 months) and nursing home residency (potentially inappropriate medication: OR 1.94, 95% CI 1.12–3.36 at 12 months), while significant associations were found for fall history and number of comorbidities.

CONCLUSION: Potentially inappropriate prescriptions remain highly prevalent in multimorbid, older adults and do not clearly improve over time. Frequent changes at patient level and dynamic shifts in specific potentially inappropriate medications/potential prescribing omissions over time underscore the need for individualised, continuous medication reviews addressing both over- and underprescribing. Factors associated with increasing potentially inappropriate prescriptions over time may serve as indicators of high-risk patients and highlight the need for targeted interventions and further research.

Study registration: This study is based on data from the OPERAM trial, which was registered at ClinicalTrials.gov (NCT02986425).

References

  1. 1. Kim S, Lee H, Park J, Kang J, Rahmati M, Rhee SY, et al. Global and regional prevalence of polypharmacy and related factors, 1997-2022: an umbrella review. Arch Gerontol Geriatr. 2024 Sep;124:105465. 10.1016/j.archger.2024.105465
  2. 2. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015 Apr;13(1):74. 10.1186/s12916-015-0322-7
  3. 3. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing. 2013 Jan;42(1):62–9. 10.1093/ageing/afs100
  4. 4. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Oct;17(1):230. 10.1186/s12877-017-0621-2
  5. 5. Baré M, Lleal M, Ortonobes S, Gorgas MQ, Sevilla-Sánchez D, Carballo N, et al.; MoPIM study group. Factors associated to potentially inappropriate prescribing in older patients according to STOPP/START criteria: MoPIM multicentre cohort study. BMC Geriatr. 2022 Jan;22(1):44. 10.1186/s12877-021-02715-8
  6. 6. Roux B, Sirois C, Simard M, Gagnon ME, Laroche ML. Potentially inappropriate medications in older adults: a population-based cohort study. Fam Pract. 2020 Mar;37(2):173–9. 10.1093/fampra/cmz060
  7. 7. Nothelle SK, Sharma R, Oakes A, Jackson M, Segal JB. Factors associated with potentially inappropriate medication use in community-dwelling older adults in the United States: a systematic review. Int J Pharm Pract. 2019 Oct;27(5):408–23. 10.1111/ijpp.12541
  8. 8. O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012 Jun;29(6):437–52. 10.2165/11632610-000000000-00000
  9. 9. By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052–81. 10.1111/jgs.18372
  10. 10. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015 Mar;44(2):213–8. 10.1093/ageing/afu145
  11. 11. Galvin R, Moriarty F, Cousins G, Cahir C, Motterlini N, Bradley M, et al. Prevalence of potentially inappropriate prescribing and prescribing omissions in older Irish adults: findings from The Irish LongituDinal Study on Ageing study (TILDA). Eur J Clin Pharmacol. 2014 May;70(5):599–606. 10.1007/s00228-014-1651-8
  12. 12. Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA; OLDY (OLd people Drugs & dYsregulations) Study Group. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008 Jan;65(1):130–3. 10.1111/j.1365-2125.2007.02961.x
  13. 13. Mekonnen AB, Redley B, de Courten B, Manias E. Potentially inappropriate prescribing and its associations with health-related and system-related outcomes in hospitalised older adults: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021 Nov;87(11):4150–72. 10.1111/bcp.14870
  14. 14. Jungo KT, Streit S, Lauffenburger JC. Utilization and Spending on Potentially Inappropriate Medications by US Older Adults with Multiple Chronic Conditions using Multiple Medications. Arch Gerontol Geriatr. 2021;93:104326. 10.1016/j.archger.2020.104326
  15. 15. Weeda ER, AlDoughaim M, Criddle S. Association Between Potentially Inappropriate Medications and Hospital Encounters Among Older Adults: A Meta-Analysis. Drugs Aging. 2020 Jul;37(7):529–37. 10.1007/s40266-020-00770-1
  16. 16. Malakouti SK, Javan-Noughabi J, Yousefzadeh N, Rezapour A, Mortazavi SS, Jahangiri R, et al. A Systematic Review of Potentially Inappropriate Medications Use and Related Costs Among the Elderly. Value Health Reg Issues. 2021 Sep;25:172–9. 10.1016/j.vhri.2021.05.003
  17. 17. Hill-Taylor B, Walsh KA, Stewart S, Hayden J, Byrne S, Sketris IS. Effectiveness of the STOPP/START (Screening Tool of Older Persons’ potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016 Apr;41(2):158–69. 10.1111/jcpt.12372
  18. 18. Díaz Planelles I, Navarro-Tapia E, García-Algar Ó, Andreu-Fernández V. Prevalence of Potentially Inappropriate Prescriptions According to the New STOPP/START Criteria in Nursing Homes: A Systematic Review. Healthcare (Basel). 2023 Feb;11(3):422. 10.3390/healthcare11030422
  19. 19. Thomas RE, Thomas BC. A Systematic Review of Studies of the STOPP/START 2015 and American Geriatric Society Beers 2015 Criteria in Patients ≥ 65 Years. Curr Aging Sci. 2019;12(2):121–54. 10.2174/1874609812666190516093742
  20. 20. Fralick M, Bartsch E, Ritchie CS, Sacks CA. Estimating the Use of Potentially Inappropriate Medications Among Older Adults in the United States. J Am Geriatr Soc. 2020 Dec;68(12):2927–30. 10.1111/jgs.16779
  21. 21. Tian F, Chen Z, Zeng Y, Feng Q, Chen X. Prevalence of Use of Potentially Inappropriate Medications Among Older Adults Worldwide: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2023;6:(8):e2326910-e; https://doi.org/10.1001/jamanetworkopen.2023.26910
  22. 22. Pan S, Li S, Jiang S, Shin JI, Liu GG, Wu H, et al. Trends in Number and Appropriateness of Prescription Medication Utilization Among Community-Dwelling Older Adults in the United States: 2011-2020. J Gerontol A Biol Sci Med Sci. 2024 Jul;79(7):glae108. 10.1093/gerona/glae108
  23. 23. Thorell K, Midlöv P, Fastbom J, Halling A. Use of potentially inappropriate medication and polypharmacy in older adults: a repeated cross-sectional study. BMC Geriatr. 2020 Feb;20(1):73. 10.1186/s12877-020-1476-5
  24. 24. Moriarty F, Bennett K, Fahey T, Kenny RA, Cahir C. Longitudinal prevalence of potentially inappropriate medicines and potential prescribing omissions in a cohort of community-dwelling older people. Eur J Clin Pharmacol. 2015 Apr;71(4):473–82. 10.1007/s00228-015-1815-1
  25. 25. Damoiseaux-Volman BA, Medlock S, Raven K, Sent D, Romijn JA, van der Velde N, et al. Potentially inappropriate prescribing in older hospitalized Dutch patients according to the STOPP/START criteria v2: a longitudinal study. Eur J Clin Pharmacol. 2021 May;77(5):777–85. 10.1007/s00228-020-03052-2
  26. 26. Jungo KT, Choudhry NK, Chaitoff A, Lauffenburger JC. Associations between sex, race/ethnicity, and age and the initiation of chronic high-risk medication in US older adults. J Am Geriatr Soc. 2024 Dec;72(12):3705–18. 10.1111/jgs.19173
  27. 27. Dalleur O, Boland B, Losseau C, Henrard S, Wouters D, Speybroeck N, et al. Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. Drugs Aging. 2014 Apr;31(4):291–8. 10.1007/s40266-014-0157-5
  28. 28. Blum MR, Sallevelt BT, Spinewine A, O’Mahony D, Moutzouri E, Feller M, et al. Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial. BMJ. 2021 Jul;374(1585):n1585. 10.1136/bmj.n1585
  29. 29. Crowley EK, Sallevelt BT, Huibers CJ, Murphy KD, Spruit M, Shen Z, et al. Intervention protocol: OPtimising thERapy to prevent avoidable hospital Admission in the Multi-morbid elderly (OPERAM): a structured medication review with support of a computerised decision support system. BMC Health Serv Res. 2020 Mar;20(1):220. 10.1186/s12913-020-5056-3
  30. 30. Adam L, Moutzouri E, Baumgartner C, Loewe AL, Feller M, M’Rabet-Bensalah K, et al. Rationale and design of OPtimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people (OPERAM): a cluster randomised controlled trial. BMJ Open. 2019 Jun;9(6):e026769. 10.1136/bmjopen-2018-026769
  31. 31. Panos A. R Package that evaluates patient data for START and STOPP criteria. https://github.com/agapiospanos/StartStopp (2021). Accessed 19.06.2025.
  32. 32. Anrys P, Boland B, Degryse JM, De Lepeleire J, Petrovic M, Marien S, et al. STOPP/START version 2-development of software applications: easier said than done? Age Ageing. 2016 Sep;45(5):589–92. 10.1093/ageing/afw114
  33. 33. Anrys PM, Strauven GC, Foulon V, Degryse JM, Henrard S, Spinewine A. Potentially Inappropriate Prescribing in Belgian Nursing Homes: Prevalence and Associated Factors. J Am Med Dir Assoc. 2018 Oct;19(10):884–90. 10.1016/j.jamda.2018.06.010
  34. 34. Doherty AS, Moriarty F, Boland F, Clyne B, Fahey T, Kenny RA, et al. Prevalence of potentially inappropriate prescribing in community-dwelling older adults: an application of STOPP/START version 3 to The Irish Longitudinal Study on Ageing (TILDA). Eur Geriatr Med. 2025 Aug;16(4):1389–402. 10.1007/s41999-025-01201-3
  35. 35. Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015 Dec;71(12):1415–27. 10.1007/s00228-015-1954-410.1007/s00228-015-1954-4 doi: https://doi.org/10.1007/s00228-015-1954-4
  36. 36. Jungo KT, Ansorg AK, Floriani C, Rozsnyai Z, Schwab N, Meier R, et al. Optimising prescribing in older adults with multimorbidity and polypharmacy in primary care (OPTICA): cluster randomised clinical trial. BMJ. 2023 May;381:e074054. 10.1136/bmj-2022-074054
  37. 37. Xu Z, Liang X, Zhu Y, Lu Y, Ye Y, Fang L, et al. Factors associated with potentially inappropriate prescriptions and barriers to medicines optimisation among older adults in primary care settings: a systematic review. Fam Med Community Health. 2021 Nov;9(4):e001325. 10.1136/fmch-2021-001325
  38. 38. Herr M, Grondin H, Sanchez S, Armaingaud D, Blochet C, Vial A, et al. Polypharmacy and potentially inappropriate medications: a cross-sectional analysis among 451 nursing homes in France. Eur J Clin Pharmacol. 2017 May;73(5):601–8. 10.1007/s00228-016-2193-z
  39. 39. Rane PP, Guha S, Chatterjee S, Aparasu RR. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm. 2017;13(2):358–63. 10.1016/j.sapharm.2016.02.012
  40. 40. Morin L, Laroche ML, Texier G, Johnell K. Prevalence of Potentially Inappropriate Medication Use in Older Adults Living in Nursing Homes: A Systematic Review. J Am Med Dir Assoc. 2016 Sep;17(9):862.e1–9. 10.1016/j.jamda.2016.06.011
  41. 41. Redston MR, Hilmer SN, McLachlan AJ, Clough AJ, Gnjidic D. Prevalence of Potentially Inappropriate Medication Use in Older Inpatients with and without Cognitive Impairment: A Systematic Review. J Alzheimers Dis. 2018;61(4):1639–52. 10.3233/jad-170842 doi: https://doi.org/10.3233/JAD-170842
  42. 42. Moon A, Jang S, Kim JH, Jang S. Risk of falls or fall-related injuries associated with potentially inappropriate medication use among older adults with dementia. BMC Geriatr. 2024 Aug;24(1):699. 10.1186/s12877-024-05300-x
  43. 43. Tao L, Qu X, Gao H, Zhai J, Zhang Y, Song Y. Polypharmacy and potentially inappropriate medications among elderly patients in the geriatric department at a single-center in China: A retrospective cross-sectional study. Medicine (Baltimore). 2021 Oct;100(42):e27494. 10.1097/md.0000000000027494 doi: https://doi.org/10.1097/MD.0000000000027494
  44. 44. Lopez-Rodriguez JA, Rogero-Blanco E, Aza-Pascual-Salcedo M, Lopez-Verde F, Pico-Soler V, Leiva-Fernandez F, et al.; MULTIPAP group. Potentially inappropriate prescriptions according to explicit and implicit criteria in patients with multimorbidity and polypharmacy. MULTIPAP: A cross-sectional study. PLoS One. 2020 Aug;15(8):e0237186. 10.1371/journal.pone.0237186
  45. 45. Hansen CR, Byrne S, Cullinan S, O’Mahony D, Sahm LJ, Kearney PM. Longitudinal patterns of potentially inappropriate prescribing in early old-aged people. Eur J Clin Pharmacol. 2018 Mar;74(3):307–13. 10.1007/s00228-017-2364-6
  46. 46. Moriarty F, Bennett K, Fahey T, Kenny RA, Cahir C. Longitudinal prevalence of potentially inappropriate medicines and potential prescribing omissions in a cohort of community-dwelling older people. Eur J Clin Pharmacol. 2015 Apr;71(4):473–82. 10.1007/s00228-015-1815-1
  47. 47. Morgan SG, Weymann D, Pratt B, Smolina K, Gladstone EJ, Raymond C, et al. Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. Age Ageing. 2016 Jul;45(4):535–42. 10.1093/ageing/afw074
  48. 48. Johnell K, Weitoft GR, Fastbom J. Sex differences in inappropriate drug use: a register-based study of over 600,000 older people. Ann Pharmacother. 2009 Jul;43(7):1233–8. 10.1345/aph.1m147 doi: https://doi.org/10.1345/aph.1M147
  49. 49. Nguyen K, Subramanya V, Kulshreshtha A. Risk Factors Associated With Polypharmacy and Potentially Inappropriate Medication Use in Ambulatory Care Among the Elderly in the United States: A Cross-Sectional Study. Drugs Real World Outcomes. 2023 Sep;10(3):357–62. 10.1007/s40801-023-00358-2
  50. 50. Boyd A, Van de Velde S, Pivette M, Ten Have M, Florescu S, O’Neill S, et al.; EU-WMH investigators. Gender differences in psychotropic use across Europe: results from a large cross-sectional, population-based study. Eur Psychiatry. 2015 Sep;30(6):778–88. 10.1016/j.eurpsy.2015.05.001
  51. 51. Lang PO, Hasso Y, Dramé M, Vogt-Ferrier N, Prudent M, Gold G, et al. Potentially inappropriate prescribing including under-use amongst older patients with cognitive or psychiatric co-morbidities. Age Ageing. 2010 May;39(3):373–81. 10.1093/ageing/afq031
  52. 52. Suzuki Y, Shiraishi N, Komiya H, Sakakibara M, Akishita M, Kuzuya M. Potentially inappropriate medications increase while prevalence of polypharmacy/hyperpolypharmacy decreases in Japan: A comparison of nationwide prescribing data. Arch Gerontol Geriatr. 2022;102:104733. 10.1016/j.archger.2022.104733
  53. 53. Oktora MP, Alfian SD, Bos HJ, Schuiling-Veninga CC, Taxis K, Hak E, et al. Trends in polypharmacy and potentially inappropriate medication (PIM) in older and middle-aged people treated for diabetes. Br J Clin Pharmacol. 2021 Jul;87(7):2807–17. 10.1111/bcp.14685
  54. 54. Bruin-Huisman L, Abu-Hanna A, van Weert HC, Beers E. Potentially inappropriate prescribing to older patients in primary care in the Netherlands: a retrospective longitudinal study. Age Ageing. 2017 Jul;46(4):614–9. 10.1093/ageing/afw243
  55. 55. Drusch S, Le Tri T, Ankri J, Zureik M, Herr M. Decreasing trends in potentially inappropriate medications in older people: a nationwide repeated cross-sectional study. BMC Geriatr. 2021 Nov;21(1):621. 10.1186/s12877-021-02568-1
  56. 56. Cole JA, Gonçalves-Bradley DC, Alqahtani M, Barry HE, Cadogan C, Rankin A, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2023 Oct;10(10):CD008165. 10.1002/14651858.cd008165.pub5 doi: https://doi.org/10.1002/14651858.CD008165.pub5
  57. 57. Sibille FX, de Saint-Hubert M, Henrard S, Aubert CE, Goto NA, Jennings E, et al. Benzodiazepine Receptor Agonists Use and Cessation Among Multimorbid Older Adults with Polypharmacy: Secondary Analysis from the OPERAM Trial. Drugs Aging. 2023 Jun;40(6):551–61. 10.1007/s40266-023-01029-1
  58. 58. Gagliano V, Salemme G, Ceschi A, Greco A, Grignoli N, Clivio L, et al. Antipsychotic, benzodiazepine and Z-drug prescriptions in a Swiss hospital network in the Choosing Wisely and COVID-19 eras: a longitudinal study. Swiss Med Wkly. 2024 Nov;154(11):3409. 10.57187/s.3409
  59. 59. Weymann D, Gladstone EJ, Smolina K, Morgan SG. Long-term sedative use among community-dwelling adults: a population-based analysis. CMAJ Open. 2017 Mar;5(1):E52–60. 10.9778/cmajo.20160056